Dossier assessment

Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-100
Last updated

Report documents

  1. Extract of dossier assessment

    Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 810 kB, EN, not accessible
  2. Dossier assessment

    Daratumumab (systemic light chain amyloidosis) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 3 MB, DE, not accessible

Dossier assessment

Indication:

Adult patients with newly diagnosed systemic light chain amyloidosis

Result of dossier assessment:
  • Patients for whom bortezomib + cyclophosphamide + dexamethasone is the best individual choice: hint of minor added benefit.
  • Patients for whom a therapy other than bortezomib + cyclophosphamide + dexamethasone is the best individual choice: added benefit not proven.

Project details

Project no.
A21-100
Commission
Commission awarded on 01.08.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Daratumumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V

    Project no.
    G16-02
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-40
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-66
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-14
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-15
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-101
    Last updated

    Status: Commission completed

  7. Dossier assessment

    Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-109
    Last updated

    Status: Commission completed

  8. Dossier assessment

    Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-127
    Last updated

    Status: Commission completed

  9. Dossier assessment

    Daratumumab (systemic light chain amyloidosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-40
    Last updated

    Status: Commission completed

  10. Dossier assessment

    Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

    Project no.
    A22-40
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form